Login to Your Account



Toxicity troubles halt Mirna's phase I trial of microRNA mimic MRX34

By Jennifer Boggs
Managing Editor

Wednesday, September 21, 2016

Reports of a fifth patient experiencing immune-related adverse events is prompting Mirna Therapeutics Inc. to close out its phase I trial testing microRNA mimic MRX34 and to "reassess where we stand with our pipeline now," according to President and CEO Paul Lammers.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription